Role of FDG-PET in the diagnosis and management of lung cancer

Expert Review of Anticancer Therapy

Volumn 4, Issue 4, 2004, Pages 561-567

  Oyen, Wim J G ^a   Bussink, Jan ^a   Verhagen, Ad F T ^a   Corstens, Frans H M ^a   Bootsma, Gerben P ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

Author keywords

FDG; Lung cancer; PET; Positron emission tomography; Radiotherapy; Staging; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PLATINUM DERIVATIVE;

ADRENAL METASTASIS; BENIGN TUMOR; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MEDIASTINOSCOPY; OUTCOMES RESEARCH; POSITRON EMISSION TOMOGRAPHY; PREDICTION; REVIEW; THORACOTOMY; TREATMENT OUTCOME; TREATMENT PLANNING; VALIDATION PROCESS;

EID: 4444239024     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.4.561     Document Type: Review

References (55)

1. 18F-FDG. J. Nucl. Med. 44, 1426-1431 (2003).
2. 15O and positron emission tomography. Clin. Cancer Res. 8, 2109-2115 (2002).
3. Laverman P, Boerman OC, Corstens FHM, Oyen WJG. Fluorinated amino acids for tumour imaging with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging 29, 681-690 (2002).
4. 18F]-fluoromisonidazole positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys. 33, 391-398 (1995).
5. American Thoracic Society/European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am. J. Respir. Crit. Care Med. 156, 320-332 (1997).
6. Reske SN, Kotzerke J. FDG-PET for clinical use. Eur. J. Nucl. Med. 28, 1707-1723 (2001).
7. Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285, 914-924 (2001).
8. Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med. 348, 2500-2507 (2003).
9. Dillemans B, Deneffe G, Verschakelen J et al. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer: a study of 569 patients. Eur. J. Cardiothorac. Surg. 8, 37-42 (1994).
10. Hammoud ZT, Anderson RC, Meyers BF et al. The current role of mediastinoscopy in the evaluation of thoracic disease. J. Thorac. Cardiovasc. Surg. 118, 894-899 (1999).
11. Gdeedo A, van Schil P, Corthouts B et al. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur. Respir. J. 10, 1547-1551 (1997).
12. Vansteenkiste JF, Stroobants SG, De Leyn PR et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J. Clin. Oncol. 16, 2142-2149 (1998).
13. Pieterman RM, van Putten JW, Meuzelaar JJ et al. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N. Engl. J. Med. 343, 254-261 (2000).
14. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 123, 137S-146S (2003).
15. Gould MY, Kuschner WG, Rydzak CE et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann. Intern. Med. 139, 879-892 (2003).
16. Verhagen AF, Bootsma GP, Tjan-Heijnen VC et al. FDG-PET in staging lung cancer; how does it change the algorithm? Lung Cancer 44, 175-181 (2004).
17. Valk PE, Pounds TR, Hopkins DM et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann. Thorac. Surg. 60, 1573-1582 (1995).
18. van Tinteren H, Hoekstra OS, Smit EF et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 359, 1388-1392 (2002).
19. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: preliminary prospective evaluation. Radiology 191, 371-377 (1994).
20. 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur. Respir. J. 10, 2529-2534 (1997).
21. Weder W, Schmid RA, Bruchhaus H et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann. Thorac. Surg. 66, 886-893 (1998).
22. Gupta NC, Graeber GM, Tamim WJ, Rogers JS, Irisari L, Bishop HA. Clinical utility of PET-FDG imaging in differentiation of benign from malignant adrenal masses in lung cancer. Clin. Lung Cancer 3, 59-64 (2001).
23. Higashi K, Matsunari I, Ueda Y et al. Value of whole-body FDG PET in management of lung cancer. Ann. Nucl. Med. 17, 1-14 (2003).
24. Inoue T, Kim EE, Komaki R et al. Detecting recurrent or residual lung cancer with FDG-PET. J. Nucl. Med. 36, 788-793 (1995).
25. 18F]-fluoro-2-deoxy-D-glucose. Radiology 191, 337-382 (1994).
26. Frank A, Lefkowitz D, Jaeger S et al. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int. J. Radiat. Oncol. Biol. Phys. 32, 1495-1512 (1995).
27. Kalff V, Hicks RJ, MacManus MP et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J. Clin. Oncol. 19, 111-118 (2001).
28. Hicks RJ, Kalff V, MacManus MP et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J. Nucl. Med. 42, 1605-1613 (2001).
29. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer a decision analysis. Ann. Thorac. Surg. 66, 1876-1883 (1998).
30. Gambhir SS, Shepherd JE, Shah BD et al. Analytical decision model for the cost-effective management of solitary pulmonary nodules. J. Clin. Oncol. 16, 2113-2125 (1998).
31. Gould MK, Sanders GD, Barnett PG et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann. Intern. Med. 138, 724-735 (2003).
32. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J. Nucl. Med. 37, 1428-1436 (1996).
33. Verboom P, van Tinteren H, Hoekstra OS et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur. J. Nucl. Med. Mol. Imaging 30, 1444-1449 (2003).
34. Hauber HP, Bohuslavizki KH, Lund CH et al. Positron emission tomography in the staging of small cell lung cancer - a preliminary study. Chest 119, 950-954 (2001).
35. Schumacher T, Brink I, Mix M et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur. J. Nucl. Med. 28, 483-488 (2001).
36. Chin R, McCain TW, Miller AA et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 37, 1-6 (2002).
37. 18F]-FDG-PET imaging in small cell lung cancer. Eur. J. Nucl. Med. 30, 78-84 (2003).
38. Erdi YE, Macapinlac H, Rosenzweig KE et al. Use of PET to monitor the response of lung cancer to radiation treatment. Eur. J. Nucl. Med. 27, 861-866 (2000).
39. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int. J. Radiat. Oncol. Biol. Phys. 44, 593-597 (1999).
40. Bradley JD, Perez CA, Dehdashti F, Siegel BA. Implementing biologic target volumes in radiation treatment planning for non-small cell lung cancer. J. Nucl. Med. 45, 96S-101S (2004).
41. Ciernik IF, Dizendorf E, Baumert BG et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int. J. Radiat. Oncol. Biol. Phys. 57, 853-863 (2003).
42. Mah K, Caldwell C, Ung Y et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small cell lung carcinoma: a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 52, 339-350 (2002).
43. Vogel WV, Oyen WJG, Barentsz JO, Kaanders JHAM, Corstens FHM. PET-CT: panacea, redundancy, or something in between? J. Nucl. Med. 45, 15S-24S (2004).
44. Munley MT, Marks LB, Scarfone C et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 23, 105-114 (1999).
45. 18F-deoxyglucose (FDG) image fusion or optimization on conformal radiotherapy in lung cancers. Int. J. Radiat. Oncol. Biol. Phys. 49, 1249-1257 (2001).
46. MacManus MP, Hicks RJ, Ball DL et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 92, 896-895 (2001).
47. Bradley J, Thorstad WL, Mutic S et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 59, 78-86 (2004).
48. 18F]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196, 167-173 (1995).
49. Weber WA, Ziegler SI, Thodtmann R et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J. Nucl. Med. 40, 1771-1777 (1999).
50. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur. J. Cancer 35, 1773-1782 (1999).
51. Vansteenkiste JF, Stroobants SG, De Leyn PR et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective pilot study. Ann. Oncol. 9, 1193-1198 (1998).
52. Akhurst T, Downey RJ, Ginsberg MS et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann. Thorac. Surg. 73, 259-264 (2002).
53. Ryu JS, Choi NC, Fischman AJ et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 35, 179-187 (2002).
54. MacManus MP, Hicks RJ, Matthews JP et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 21, 1285-1292 (2003).
55. Weber WA, Petersen V, Schmidt B et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J. Clin. Oncol. 21, 2651-2657 (2003).